Trials / Terminated
TerminatedNCT03397394
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Conditions
- Bladder Cancer
- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Renal Pelvis Carcinoma
- Ureter Carcinoma
- Urinary Bladder Carcinoma
- Urethra Carcinoma
- Muscle Invasive Bladder Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rucaparib | Rucaparib will be administered daily. |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-12-12
- Completion
- 2020-01-15
- First posted
- 2018-01-12
- Last updated
- 2023-06-09
- Results posted
- 2020-10-19
Locations
64 sites across 6 countries: United States, France, Germany, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03397394. Inclusion in this directory is not an endorsement.